228 related articles for article (PubMed ID: 1736009)
1. c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
Rosti V; Bergamaschi G; Ponchio L; Cazzola M
Leukemia; 1992 Jan; 6(1):1-7. PubMed ID: 1736009
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
Szczylik C; Skórski T; Malaguarnera L; Hetman J; Chen ST; Calabretta B
Folia Histochem Cytobiol; 1996; 34(3-4):129-34. PubMed ID: 8967957
[TBL] [Abstract][Full Text] [Related]
3. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Skórski T; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation.
Murohashi I; Endho K; Nishida S; Yoshida S; Jinnai I; Bessho M; Hirashima K
Exp Hematol; 1995 Aug; 23(9):970-7. PubMed ID: 7543418
[TBL] [Abstract][Full Text] [Related]
5. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
de Fabritiis P; Amadori S; Calabretta B; Mandelli F
Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
[TBL] [Abstract][Full Text] [Related]
6. Interaction of transforming growth factor-beta 1 with hemopoietic growth factors in the regulation of human normal and leukemic myelopoiesis.
Aglietta M; Stacchini A; Severino A; Sanavio F; Ferrando ML; Piacibello W
Exp Hematol; 1989 Mar; 17(3):296-9. PubMed ID: 2783914
[TBL] [Abstract][Full Text] [Related]
7. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
[TBL] [Abstract][Full Text] [Related]
8. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Hijiya N; Catani L; DeRiel K; Luger SM; McGlave P; Gewirtz AM
Blood; 1992 Apr; 79(8):1956-61. PubMed ID: 1562723
[TBL] [Abstract][Full Text] [Related]
9. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
[TBL] [Abstract][Full Text] [Related]
10. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C
Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.
Lanza F; Bi S; Moretti S; Castoldi G; Goldman JM
Br J Haematol; 1995 May; 90(1):8-14. PubMed ID: 7786800
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
[TBL] [Abstract][Full Text] [Related]
15. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
16. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor and human hematopoiesis: II. Inhibition and mode of action on normal and chronic myelogenous leukemia-derived granulocyte-macrophage progenitor cells.
Beran M; O'Brien S; Andersson B; McCredie KB; Gutterman JU
Hematol Pathol; 1988; 2(2):65-71. PubMed ID: 3143710
[TBL] [Abstract][Full Text] [Related]
18. Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors.
Rosti V; Bergamaschi G; Lucotti C; Danova M; Carlo-Stella C; Locatelli F; Tonon L; Mazzini G; Cazzola M
Blood; 1995 Nov; 86(9):3387-93. PubMed ID: 7579442
[TBL] [Abstract][Full Text] [Related]
19. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
Chasty R; Whetton A; Lucas G
Leuk Res; 1996 May; 20(5):391-5. PubMed ID: 8683978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
